FDA to Investigate ARBs and Possible Cancer Risk
31 July 2010
No Comment
A recent meta-analysis published in Lancet Oncology has prompted the FDA to begin a review the safety of angiotensin receptor blockers after the study found that ARBs may be associated with an increase in cancer rates.
For more information visit “FDA to look into possible cancer risk with ARBs” by Lisa Nainggolan which can be found at http://www.theheart.org/article/1099535.do.
Leave your response!
You must be logged in to post a comment.